HELP - Cybin Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$15.50
DETAILS
HIGH:
$16.00
LOW:
$15.00
MEDIAN:
$15.50
CONSENSUS:
$15.50
UPSIDE:
49.18%
About Cybin Inc. Common Stock (https://www.helus.com)
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Eric So | Co-Founder, Interim CEO, President & Executive Chairman | 1976 | $695,846 CAD |
| Paul Glavine | Co-Founder, Chief Growth Officer & Director | 1990 | $695,846 CAD |
| John Kanakis | Co-Founder | 1981 | $682,172 CAD |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary | 1976 | $507,388 CAD |
| George Tziras | Chief Business Officer | 1981 | $494,026 CAD |
| Greg Cavers | Chief Financial Officer | 1971 | $483,226 CAD |
| Aaron Bartlone | Chief Operating Officer | 1967 | $441,721 CAD |
| Alex L. Nivorozhkin | Chief Scientific Officer | 1960 | – |
| Allison House-Gecewicz | Senior Vice President of Clinical Operations | – | – |
| Douglas Sommerville | Chief Pharmaceutical Strategist | – | – |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer | – | – |
| Sara Brittany Somerset | Chief Communications Officers | – | – |